BlackRock’s SpyGlass Pharma SGP Stock Holding History

BlackRock’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.4M	Sell	630,409 -81,303	-11%	-$2M	﹤0.01%	3362
2026 Q2	$15.8M	Buy	711,712 +566,973	+392%	+$12.3M	﹤0.01%	3415
2026 Q1	$3.75M	Buy	+144,739	New	+$3.89M	﹤0.01%	3939

Other funds holding SGP

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $116B AUM 33.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock's SGP Position: Q3 2026 in Review

BlackRock reduced its SpyGlass Pharma (SGP) stake by 11% in Q3 2026, selling an estimated $2M and leaving 630,409 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3362.

BlackRock first reported a position in SGP in Q1 2026 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

BlackRock held 630,409 shares of SpyGlass Pharma worth $16.4M as of Q3 2026.
BlackRock sold 81,303 SpyGlass Pharma shares in Q3 2026, an estimated $2M.
SpyGlass Pharma made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #3362 holding.
BlackRock first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 3 quarters since.
47 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.